Therapeutic Repurposing of Antiviral Drugs Available for COVID-19 Therapy: A Mini Review
| Autor: | Nadia Bounoua, Khaldun M. Al Azzam, Hassan Y. Aboul-Enein, Mohamed Nadjib Rebizi, El-Sayed Negim |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Asian Journal of Chemistry. 34:1993-1996 |
| ISSN: | 0975-427X 0970-7077 |
| DOI: | 10.14233/ajchem.2022.23819 |
| Popis: | The impact of repurposing drugs that now in vitro inhibit significant chronic respiratory illness corona virus type 2 was indeed underestimated or ignored during the early phases of the COVID-19 virus. Recent clinical data, however, suggest that remdesivir and favipiravir may hasten to heal, but lopinavir/ritonavir had minimal impact on very ill patients. The interferon appears to be the primary impact of triple therapy with ribavirin, lopinavir and interferon-1b. The role of hydroxychloroquine, marketed as Plaquenil® or chloroquine, marketed as Aralen®, in the treatment and prevention of COVID-19 is presently unknown due to the small sample size research. Anti-cytokine drugs may not benefit persons with mild disease or severe illness. Traditional Chinese medicine (TCM) is commonly used for COVID-19 patients in China and has antiviral and immunomodulatory effects on SARS-CoV-2. This review outlines existing COVID-19 therapeutic options and advocates for clinical trials for children, persons with mild disease and those in the early stages of COVID-19. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|